专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009017464A9 RELATION EXTRACTION SYSTEM 审中-公开
公开(公告)号：WO2009017464A9
公开(公告)日：2009-02-05
申请号：PCT/SG2008/000281
申请日：2008-07-31
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , YONG, Stanely, Wai, Keong , SU, Jian , YANG, Xiao, Feng
发明人： YONG, Stanely, Wai, Keong , SU, Jian , YANG, Xiao, Feng
IPC分类号： G06F17/21 , G10L13/08 , G01L15/00
摘要： A classification system comprising a first supervised classifier module configured to access an annotated corpus during a training mode, a second semi-supervised module configured to access a raw text and index at least one pseudo document extracted from the raw text according to the location of a skip bigram within the at least one pseudo document during the training mode, a third classifier module configured to receive the output of the first supervised classifier module and a plurality of skip bigram similarity features derived from the skip bigram from the second semi-supervised module during a validation mode, and to receive a raw text document for relation extraction during a normal operation mode. Also a method.

2. 发明申请

WO2008057795A2 NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA 审中-公开
标题翻译：新生儿多发性肿瘤抗利什曼抗体肿瘤免疫反应在多发性甲状旁腺病患者亚组中的研究
公开(公告)号：WO2008057795A2
公开(公告)日：2008-05-15
申请号：PCT/US2007/082605
申请日：2007-10-26
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , YANG, Xiao-Feng
发明人： YANG, Xiao-Feng
IPC分类号： C12Q1/70
CPC分类号： C07K16/30
摘要： The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'untranslated region (3'UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.
摘要翻译：
本发明提供了新颖的抗原，MPD5，PV13，和PV65，属于该组不进行常规的基因组结构隐藏抗原，并通过位于所述3'非翻译区域的隐蔽开放阅读框（编码 3'UTR）的肌营养蛋白mRNA。抗原在PV患者亚群以及慢性粒细胞白血病和前列腺癌患者中引发IgG抗体应答。 MPD5，PV13和PV65的翻译由开放阅读框上游的新型内部核糖体进入位点（IRES）介导。在患有骨髓增生性疾病的患者中引发针对MPD5，PV13和/或PV65抗原的抗肿瘤免疫应答是一种新颖的免疫疗法。

3. 发明申请

WO02088380A9 IMMUNOGENIC TUMOR ANTIGENS: NUCLEIC ACIDS AND POLYPEPTIDES ENCODING THE SAME AND METHODS OF USE THEREOF 审中-公开
标题翻译：免疫原性肿瘤抗原：核酸和多核苷酸编码它们及其使用方法
公开(公告)号：WO02088380A9
公开(公告)日：2004-04-29
申请号：PCT/US0213693
申请日：2002-05-02
申请人： DANA FARBER CANCER INST INC , RITZ JEROME , YANG XIAO-FENG , WU CATHERINE J
发明人： RITZ JEROME , YANG XIAO-FENG , WU CATHERINE J
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K16/30 , A61K39/395 , C07K16/00
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/505 , A61K2039/53 , C07K16/3061
摘要： The invention provides human chronic myelocytic leukemia-like proteins (CML protein) and isolated nucleic acid molecules encoding the same. Also provided are antibodies that immunospecifically-bind to CML polypeptides or polynucleotides, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which CML polypeptides, polynucleotides, and antibodies are used in the detection, prevention, and treatment of a broad range of pathological states, and methods of treating malignancy-related disorders by modulating activity or expression of CML proteins.
摘要翻译：本发明提供人类慢性骨髓性白血病样蛋白（CML蛋白）和编码其的分离的核酸分子。还提供了免疫特异性结合CML多肽或多核苷酸或其衍生物，变体，突变体或其片段的抗体。本发明还提供了CML多肽，多核苷酸和抗体用于检测，预防和治疗广泛病理状态的方法，以及通过调节CML蛋白的活性或表达来治疗恶性肿瘤相关疾病的方法。

4. 发明申请

WO2008057795A9 NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA 审中-公开
标题翻译：新生儿多发性肿瘤抗利什曼抗体肿瘤免疫反应在多发性甲状旁腺病患者亚组中的研究
公开(公告)号：WO2008057795A9
公开(公告)日：2008-12-31
申请号：PCT/US2007082605
申请日：2007-10-26
申请人： UNIV TEMPLE , YANG XIAO-FENG
发明人： YANG XIAO-FENG
IPC分类号： C12Q1/68
CPC分类号： C07K16/30
摘要： The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'untranslated region (3'UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.
摘要翻译：本发明提供了新的抗原，MPD5，PV13和PV65，其属于无常规基因组结构的隐性抗原组，并且由位于肌营养素mRNA的3'非翻译区（3'UTR）中的隐蔽性开放阅读框编码。抗原在PV患者亚群以及慢性粒细胞白血病和前列腺癌患者中引发IgG抗体应答。 MPD5，PV13和PV65的翻译由开放阅读框上游的新型内部核糖体进入位点（IRES）介导。在患有骨髓增生性疾病的患者中引发针对MPD5，PV13和/或PV65抗原的抗肿瘤免疫应答是一种新颖的免疫疗法。

5. 发明申请

WO2008057795A3 NOVEL TUMOR ANTIGENS ELICIT ANTI-TUMOR HUMORAL IMMUNE REACTIONS IN A SUBSET OF PATIENTS WITH POLYCYTHEMIA VERA 审中-公开
标题翻译：新型肿瘤抗原在多发性硬化症患者中的抗肿瘤免疫反应
公开(公告)号：WO2008057795A3
公开(公告)日：2008-10-30
申请号：PCT/US2007082605
申请日：2007-10-26
申请人： UNIV TEMPLE , YANG XIAO-FENG
发明人： YANG XIAO-FENG
IPC分类号： C12Q1/68
CPC分类号： C07K16/30
摘要： The invention provides novel antigens, MPD5, PV13, and PV65, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'untranslated region (3'UTR) of myotrophin mRNA. The antigens elicit IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD5, PV13 and PV65 was mediated by a novel internal ribosome entry site (IRES) upstream of the open reading frame. Eliciting anti-tumor immune response against MPD5, PV13 and/or PV65 antigen in patients with myeloproliferative diseases is a novel immunotherapy.
摘要翻译：本发明提供新型抗原，MPD5，PV13和PV65，属于没有常规基因组结构的隐性抗原组，由位于肌营养蛋白mRNA的3'非翻译区（3'UTR）的隐性开放阅读框编码。抗原在PV患者的一个子集中以及患有慢性骨髓性白血病和前列腺癌的患者中引起IgG抗体应答。 MPD5，PV13和PV65的翻译由开放阅读框架上游的新型内部核糖体进入位点（IRES）介导。在骨髓增生性疾病患者中引起针对MPD5，PV13和/或PV65抗原的抗肿瘤免疫应答是一种新型免疫治疗。

6. 发明申请

WO2008022253A3 AN UNCONVENTIONAL ANTIGEN TRANSLATED BY A NOVEL INTERNAL RIBOSOME ENTRY SITE ELICITS ANTITUMOR HUMORAL IMMUNE REACTIONS 审中-公开
标题翻译：一个新的内部RIBOSOME入口站点翻译的非传统抗原引发抗肿瘤免疫反应
公开(公告)号：WO2008022253A3
公开(公告)日：2008-10-30
申请号：PCT/US2007076088
申请日：2007-08-16
申请人： UNIV TEMPLE , YANG XIAO-FENG
发明人： YANG XIAO-FENG
IPC分类号： C07H21/02 , A01N43/04 , A01N63/00 , A01N65/00 , A61K38/00 , C07H21/04 , C12N5/00
CPC分类号： C07K14/4702 , A61K39/00 , A61K39/0011 , A61K2039/53 , C07K14/4748 , C12N2840/002 , C12N2840/105 , C12N2840/203 , C12N2840/85
摘要： The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'untranslated region (3'UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-a stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-a stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy.
摘要翻译：本发明提供了一种新型抗原MPD6，其属于无常规基因组结构并且由位于肌营养蛋白mRNA的3'非翻译区（3'UTR）中的隐蔽性开放阅读框编码的神秘抗原组。 MPD6在一部分PV患者以及慢性粒细胞白血病和前列腺癌患者中引发IgG抗体应答。 MPD6的翻译由MPD6阅读框上游的新型内部核糖体进入位点（IRES）介导。此外，MPD6-IRES介导的翻译，但不是肌营养不良MPD6转录，响应IFN-α刺激而显着上调。这些发现表明，一种新的IRES介导的机制负责翻译非常规自身抗原MPD6对IFN-α刺激的反应。在骨髓增殖性疾病患者中针对非常规抗原MPD6引发的抗肿瘤免疫应答表明MPD6作为新型免疫疗法的靶标。

7. 发明申请

WO2002088380A3 IMMUNOGENIC TUMOR ANTIGENS: NUCLEIC ACIDS AND POLYPEPTIDES ENCODING THE SAME AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2002088380A3
公开(公告)日：2002-11-07
申请号：PCT/US2002/013693
申请日：2002-05-02
申请人： DANA-FARBER CANCER INSTITUTE, INC. , RITZ, Jerome , YANG, Xiao-Feng , WU, Catherine, J.
发明人： RITZ, Jerome , YANG, Xiao-Feng , WU, Catherine, J.
IPC分类号： A61K39/395
摘要： The invention provides human chronic myelocytic leukemia-like proteins (CML protein) and isolated nucleic acid molecules encoding the same. Also provided are antibodies that immunospecifically-bind to CML polypeptides or polynucleotides, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which CML polypeptides, polynucleotides, and antibodies are used in the detection, prevention, and treatment of a broad range of pathological states, and methods of treating malignancy-related disorders by modulating activity or expression of CML proteins.

8. 发明申请

WO2008022253A8 AN UNCONVENTIONAL ANTIGEN TRANSLATED BY A NOVEL INTERNAL RIBOSOME ENTRY SITE ELICITS ANTITUMOR HUMORAL IMMUNE REACTIONS 审中-公开
标题翻译：一个新的内部入侵者网站转载的非传统抗原抗体抗体免疫反应
公开(公告)号：WO2008022253A8
公开(公告)日：2009-08-06
申请号：PCT/US2007076088
申请日：2007-08-16
申请人： UNIV TEMPLE , YANG XIAO-FENG
发明人： YANG XIAO-FENG
IPC分类号： C07H21/02 , A01N43/04 , A01N63/00 , A01N65/00 , A61K38/00 , C07H21/04 , C12N5/00
CPC分类号： C07K14/4702 , A61K39/00 , A61K39/0011 , A61K2039/53 , C07K14/4748 , C12N2840/002 , C12N2840/105 , C12N2840/203 , C12N2840/85
摘要： The invention provides a novel antigen, MPD6, which belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3'untranslated region (3'UTR) of myotrophin mRNA. MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer. The translation of MPD6 was mediated by a novel internal ribosome entry site (IRES) upstream of the MPD6 reading frame. Furthermore, the MPD6-IRES mediated translation, but not myotrophin-MPD6 transcription, was significantly upregulated in response to IFN-a stimulation. These findings demonstrate that a novel IRES-mediated mechanism is responsible for the translation of unconventional self-antigen MPD6 in responsive to IFN-a stimulation. The eliciting anti-tumor immune response against unconventional antigen MPD6 in patients with myeloproliferative diseases indicates MPD6 as a target of novel immunotherapy.
摘要翻译：本发明提供了一种新颖的抗原，MPD6属于没有常规基因组结构的隐性抗原组，由位于肌营养蛋白mRNA的3'非翻译区（3'UTR）的隐性开放阅读框编码。 MPD6在PV患者的一个子集以及慢性骨髓性白血病和前列腺癌患者中引发IgG抗体应答。 MPD6的翻译由MPD6阅读框上游的新型内部核糖体进入位点（IRES）介导。此外，MPD6-IRES介导的翻译，但不是myotrophin-MPD6转录，在对IFN-α刺激的响应中显着上调。这些研究结果表明，一种新的IRES介导的机制负责非传统的自身抗原MPD6在IFN-α刺激反应中的翻译。在骨髓增生性疾病患者中引发针对非常规抗原MPD6的抗肿瘤免疫应答表明MPD6是新型免疫治疗的靶标。

9. 发明申请

WO2009017464A1 RELATION EXTRACTION SYSTEM 审中-公开
标题翻译：关系抽取系统
公开(公告)号：WO2009017464A1
公开(公告)日：2009-02-05
申请号：PCT/SG2008000281
申请日：2008-07-31
申请人： AGENCY SCIENCE TECH & RES , YONG STANELY WAI KEONG , SU JIAN , YANG XIAO FENG
发明人： YONG STANELY WAI KEONG , SU JIAN , YANG XIAO FENG
IPC分类号： G06F17/21 , G01L15/00 , G10L13/08
CPC分类号： G06F17/2715
摘要： A classification system comprising a first supervised classifier module configured to access an annotated corpus during a training mode, a second semi-supervised module configured to access a raw text and index at least one pseudo document extracted from the raw text according to the location of a skip bigram within the at least one pseudo document during the training mode, a third classifier module configured to receive the output of the first supervised classifier module and a plurality of skip bigram similarity features derived from the skip bigram from the second semi-supervised module during a validation mode, and to receive a raw text document for relation extraction during a normal operation mode. Also a method.
摘要翻译：一种分类系统，包括：第一监督分类器模块，被配置为在训练模式期间访问被注释的语料库;第二半监督模块，被配置为访问原始文本并且索引从原始文本提取的至少一个伪文档，在训练模式期间跳过所述至少一个伪文档内的二元组;第三分类器模块，被配置为接收所述第一监督分类器模块的输出以及从所述第二半监督模块期间从所述第二半监督模块导出的多个跳过二元组相似性特征验证模式，并且在正常操作模式期间接收用于关系提取的原始文本文档。也是一种方法。

10. 发明申请

WO2008027800A3 METHOD FOR ENHANCING THE EFFICACY OF ANTIGEN SPECIFIC TUMOR IMMUNOTHERAPY 审中-公开
公开(公告)号：WO2008027800A3
公开(公告)日：2008-03-06
申请号：PCT/US2007/076717
申请日：2007-08-24
申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION , YANG, Xiao-feng
发明人： YANG, Xiao-feng
IPC分类号： G01N33/53 , C12P21/00 , C07K1/00 , C07K5/00
摘要： The invention provides a method for the improved processing efficiency of T cell tumor antigen epitopes using bioinformatic means. The proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes was compared to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. The amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, were significantly different from those of the viral antigen epitopes. These two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes, targeted activation of the immunoproteasomes and peptidases can be achieved that mediate the cleavage of viral epitopes in order to more effectively generate tumor antigen epitopes thus enhancing antigen-specific tumor immunotherapy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式